|

Afatinib Clinical Trials

11 actively recruiting trials across 1 location

Also known as: 30mg po qd, Gilotrif(Boehringer-Ingelheim), Gilotrif™, Giotrif, Targeted therapy

Other10 trials

A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
Phase 1
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
Phase 2
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
Phase 1/2
Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 1/2
Observational Study of Afatinib 30 mg Daily
Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction
Phase 2
Pilot Trial for Treatment of Recurrent Glioblastoma
Early 1
Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
Phase 1/2

Boston, Massachusetts1 trial

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Massachusetts General Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.